463The diagnostic and prognostic value of immunhisto chemical demonstration of the gamma2 chain of laminin-5 in urinary bladder urothelial carcinoma

2005 ◽  
Vol 4 (3) ◽  
pp. 118
Author(s):  
H. Wunderlich ◽  
W. Hindermann ◽  
A. Berndt ◽  
J. Schubert ◽  
O. Reichelt ◽  
...  
2003 ◽  
Vol 27 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Winfried Hindermann ◽  
Alexander Berndt ◽  
Karl M Haas ◽  
Heiko Wunderlich ◽  
Detlef Katenkamp ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 195-195
Author(s):  
Heiko Wunderlich ◽  
Winfried Hindermann ◽  
Alexander Berndt ◽  
Detlef Katenkamp ◽  
Jörg Schubert ◽  
...  

2021 ◽  
Author(s):  
Chien-Feng Li ◽  
Ti-Chun Chan ◽  
Cheng-Tang Pan ◽  
Pichpisith Pierre Vejvisithsakul ◽  
Jia-Chen Lai ◽  
...  

2014 ◽  
Vol 7 (2) ◽  
pp. 362-368 ◽  
Author(s):  
Naohiro Makise ◽  
Teppei Morikawa ◽  
Yuta Takeshima ◽  
Yukio Homma ◽  
Masashi Fukayama

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6040
Author(s):  
Michèle J. Hoffmann ◽  
Wolfgang A. Schulz

Urothelial carcinoma (UC) is the most frequent histological type of cancer in the urinary bladder. Genomic changes in UC activate MAPK and PI3K/AKT signal transduction pathways, which increase cell proliferation and survival, interfere with cell cycle and checkpoint control, and prevent senescence. A more recently discovered additional category of genetic changes in UC affects chromatin regulators, including histone-modifying enzymes (KMT2C, KMT2D, KDM6A, EZH2), transcription cofactors (CREBBP, EP300), and components of the chromatin remodeling complex SWI/SNF (ARID1A, SMARCA4). It is not yet well understood how these changes contribute to the development and progression of UC. Therefore, we review here the emerging knowledge on genomic and gene expression alterations of chromatin regulators and their consequences for cell differentiation, cellular plasticity, and clonal expansion during UC pathogenesis. Our analysis identifies additional relevant chromatin regulators and suggests a model for urothelial carcinogenesis as a basis for further mechanistic studies and targeted therapy development.


BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Shuxiong Zeng ◽  
Anwei Liu ◽  
Lihe Dai ◽  
Xiaowen Yu ◽  
Zhensheng Zhang ◽  
...  

2015 ◽  
Vol 26 (2) ◽  
pp. S13
Author(s):  
Kun-Lin Hsieh ◽  
Chi-Cheng Su ◽  
Kun-Hung Shen ◽  
Ting-Feng Wu

Cytopathology ◽  
2019 ◽  
Vol 30 (5) ◽  
pp. 510-518
Author(s):  
Antonín Brisuda ◽  
Jaromír Háček ◽  
Marcela Čechová ◽  
Petr Škapa ◽  
Marek Babjuk

2018 ◽  
Vol 119 (6) ◽  
pp. 4592-4606 ◽  
Author(s):  
Sheng-Yuan Huang ◽  
Chih-Cheng Chien ◽  
Ruey-Shyang Hseu ◽  
Victoria Ying Jen Huang ◽  
Shang Ying Chiang ◽  
...  

2012 ◽  
Vol 65 (9) ◽  
pp. 802-807 ◽  
Author(s):  
Peir-In Liang ◽  
Li-Ching Wu ◽  
Jim Jinn-Chyuan Sheu ◽  
Ting-Feng Wu ◽  
Kun-Hung Shen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document